Our first API factory in Bollaram, Hyderabad, commenced operations.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/4ca825aa33f2a8aae5669cd68867ebbee08bee63.jpg" data-entity-uuid="cf3ef9e4-277a-4fcc-9942-bffc05282127" data-entity-type="file" width="529" height="353">&nbsp;

<meta charset="utf-8"><span style="white-space:pre-wrap;">We went public on the Bombay Stock Exchange and launched APIs in India. In the 1980s, we were among the first to export APIs to the USA.</span><img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/1985a.png" data-entity-uuid="98d5c078-b4e6-4155-86e5-fb587d34bbf3" data-entity-type="file" width="434" height="264">&nbsp;

Our first pioneering mega-brand Omez (Omeprazole) was launched in India, becoming our first 100 crore brand and a leader in Indian pharma.&nbsp;&nbsp;

We expanded our operations internationally by opening a branch in Russia.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/1992.png" data-entity-uuid="a1df3428-a919-4be9-94a0-d3707a13ac99" data-entity-type="file" width="406" height="270">

Dr. Anji Reddy founded the Dr. Reddy’s Foundation to give back to society. Our CSR activities include health, education, livelihood, and sustainability.&nbsp;

We were the first Indian pharma company to out-license a novel drug to an innovator.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/1997.png" data-entity-uuid="f45e20d1-1e6d-4af6-bfa1-c94e8d3cd2dc" data-entity-type="file" width="406" height="278">&nbsp;

We became the first pharma company in Asia, outside Japan, to list on the New York Stock Exchange.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2001a.png" data-entity-uuid="7fec3a77-3508-4b9f-8990-0790048d79c7" data-entity-type="file" width="406" height="275">

We became the first Indian pharma company to obtain a 180-day marketing exclusivity from the USFDA (Fluoxetine capsules 40mg).

Our founder, Dr. Anji Reddy, received the Padma Shri from the Govt. of India. <img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/Padmashree_1.JPG" data-entity-uuid="91b7507d-a3f5-4dfb-b0d2-9e9cea60bd4b" data-entity-type="file" width="406" height="578"><img>

Aurigene Oncology Ltd, our Bengaluru subsidiary, was incorporated for drug discovery.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2002.png" data-entity-uuid="b126a2d1-c859-4368-9222-4005e1f43208" data-entity-type="file" width="404" height="270">&nbsp;

We released our first Safety, Health, Environment (SHE) report. We were also among the earliest to initiate annual voluntary sustainability disclosures from the following year.&nbsp;

We became the first Indian pharma company to launch an Authorized Generic (AG) in the U.S. (finasteride 5 mg, generic equivalent of Merck’s Proscar tabs 5 mg).

We became the fastest Indian pharma company to cross USD 1 billion in revenue.

We launched the world’s then first monoclonal antibody biosimilar of rituximab in India (Reditux).<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/injection.png" data-entity-uuid="9b242fa8-a956-4f34-acdd-57a9c0471fb5" data-entity-type="file" width="514" height="524">&nbsp;

We launched the world’s first and India’s only generic of darbepoetin alfa (Cresp).<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/lotion.png" data-entity-uuid="58499aba-5496-40a7-9791-f52a7e5cd7d7" data-entity-type="file" width="775" height="399">

We adopted 6 sustainability goals for the next decade.

Our founder, Dr. Anji Reddy, was honoured with the Padma Bhushan by the Govt. of India for his contribution to the Indian pharma industry. <img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/Dr.%20K%20Anji%20Reddy%20receving%20Padma%20Bhushan%20Award%20from%20President%20Prathiba%20Patel.jpg" data-entity-uuid="a2da9658-a99e-4981-8db4-8fdd7d561d26" data-entity-type="file" width="406" height="609">

Acquired a select portfolio of Belgium based UCBs established brands in certain South Asian countries<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2015.png" data-entity-uuid="706cbf0f-f239-490d-8538-740c28530a3d" data-entity-type="file" width="808" height="560">

We were listed on the Dow Jones Sustainability Index 2016 for Emerging Markets.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2016.png" data-entity-uuid="df8e4228-7f78-487d-b33d-39fe14d88b62" data-entity-type="file" width="404" height="244">

We entered the branded consumer health arena through the acquisition of six OTC brands from Ducere Pharma.

We entered the nutrition segment in India with the launch of Celevida, a first-of-its-kind product in Dr. Reddy’s nutrition portfolio.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2019.png" data-entity-uuid="75aa6076-3e9a-42f5-a44b-aabbbd22b311" data-entity-type="file" width="306" height="226">

We were the first foreign generics company to get approval to supply Olanzapine to China's public hospitals under the QCE system.

We became the first company in India and third in Asia&nbsp;<br>to join the Science-Based Targets initiative (SBTi).

We acquired select divisions of Wockhardt in India.

Our focus on agility, access and affordability helped us<br>reach over 5 million patients during the pandemic,&nbsp;<br>especially in low and middle income countries.

We combined in-house efforts with open-innovation&nbsp;<br>partnerships to provide a portfolio that included a vaccine and therapeutics for COVID-19.

Our company played its part along with the rest of&nbsp;<br>the pharma industry in the fight against COVID-19.

<meta charset="utf-8"><span style="white-space:pre-wrap;">Launched Lenalidomide capsule in the U.S., with two of the six strengths eligible for first-to-market, 180-day exclusivity.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2022a.png" data-entity-uuid="2ea8eba9-0f34-420c-9c33-c9656ae0ae26" data-entity-type="file" width="405" height="253"></span>

Our Hyderabad facility was recognised by the World Economic Forum as part of its Global Lighthouse Network for Industry 4.0 leadership.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2022b_0.png" data-entity-uuid="38187d94-523d-4331-973b-e9757f1efb4c" data-entity-type="file" width="257" height="250">

We were named by the prestigious Science Magazine&nbsp;as among the Top 20 employers globally in pharma/biotech. We acquired a medical cannabis company, Nimbus Health GmbH, in Germany.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/2022c_0.png" data-entity-uuid="93ee8584-fc8b-46b8-b225-f79ce5917798" data-entity-type="file" width="200" height="200">

Dr. Reddy's Foundation received a National Award from the President of India for the Empowerment of Persons with Disabilities.

We became the first Indian pharma company to debut on the Dow Jones Sustainability World Index.<br><img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/MicrosoftTeams-image%20%2836%29.png" data-entity-uuid="f83121a9-8850-4077-afde-e70502af0287" data-entity-type="file" width="468" height="400">&nbsp;

We launched Nerivio® in India for migraine management.<img src="https://websiteqa.mydrreddys.com:8443/sites/default/files/inline-images/nerivio.png" data-entity-uuid="15d11afd-48c4-4136-8e23-f7b775c9d192" data-entity-type="file" width="1178" height="1178">

Our platform ‘Celevida Wellness’ became our first D2C&nbsp;e-commerce platform in India carrying our products for&nbsp;diabetes nutrition and third-party brands.

Our proposed rituximab biosimilar dossier was accepted for review by the USFDA, MHRA and EMA.

We entered into strategic collaborations for novel&nbsp;molecules - with the U.S.-based Coya Therapeutics for&nbsp;a novel combination biologic for ALS; with China-based&nbsp;Junshi Biosciences for Toripalimab; and with Jiangsu&nbsp;Hengrui for Pyrotinib.

We were included in the Bloomberg Gender-Equality Index for the 6<span style="font-family:&quot;DRL Circular Book&quot;,sans-serif;font-size:11.0pt;line-height:107%;">^th</span> year in a row.

Partnered with Nestlé India to launch nutritional health&nbsp;solutions in India and other regions.

Acquired Menolabs' women's health and dietary&nbsp;supplements portfolio from Amyris Inc. including seven&nbsp;products for perimenopause and menopause support.

<meta charset="utf-8"><span style="white-space:pre-wrap;">Signed a definitive agreement with Haleon Plc to acquire Nicotinell and its Nicotine Replacement Therapy portfolio.</span>